FDA sched­ules ad­vi­so­ry com­mit­tee hear­ing for Lyn­parza prostate can­cer ap­pli­ca­tion

What once ap­peared to be a slam dunk for Mer­ck and As­traZeneca’s PARP in­hibitor Lyn­parza may no longer be a sure thing.

The FDA will con­vene an ad­vi­so­ry com­mit­tee to dis­cuss an ap­pli­ca­tion to fur­ther ex­pand the drug’s la­bel in­to a broad­er set of prostate can­cer pa­tients, the com­pa­nies an­nounced Thurs­day morn­ing. The hear­ing, run by the On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee, or ODAC, will take place on April 28.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN